HIK.L vs. ^GSPC

Last updated Apr 3, 2026

Compare and contrast key facts about Hikma Pharmaceuticals plc (HIK.L) and S&P 500 Index (^GSPC).

Performance

HIK.L vs. ^GSPC - Performance Comparison

The chart below illustrates the hypothetical performance of a £10,000 investment in Hikma Pharmaceuticals plc (HIK.L) and S&P 500 Index (^GSPC). The values are adjusted to include any dividend payments, if applicable.

HIK.L vs. ^GSPC - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
HIK.L Hikma Pharmaceuticals plc	-13.16%	-19.60%	14.90%	18.37%	-28.40%	-10.43%	28.87%	18.12%	54.10%	-39.16%
^GSPC S&P 500 Index	-2.04%	8.10%	25.46%	18.02%	-9.86%	28.09%	12.84%	23.98%	-0.68%	9.09%

Different Trading Currencies

HIK.L is traded in GBp, while ^GSPC is traded in USD. To make them comparable, the ^GSPC values have been converted to GBp using the latest available exchange rates.

Returns By Period

In the year-to-date period, HIK.L achieves a -13.16% return, which is significantly lower than ^GSPC's -2.36% return. Over the past 10 years, HIK.L has underperformed ^GSPC with an annualized return of -2.02%, while ^GSPC has yielded a comparatively higher 13.10% annualized return.

HIK.L

• 1D: 1.63%
• 1M: 7.94%
• YTD: -13.16%
• 6M: -26.57%
• 1Y: -29.45%
• 3Y*: -4.94%
• 5Y*: -8.15%
• 10Y*: -2.02%

^GSPC

• 1D: 0.00%
• 1M: -2.80%
• YTD: -2.36%
• 6M: -0.73%
• 1Y: 13.71%
• 3Y*: 14.30%
• 5Y*: 11.28%
• 10Y*: 13.10%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

HIK.L vs. ^GSPC — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

HIK.L

HIK.L Risk / Return Rank: 10
HIK.L Sharpe Ratio Rank: 6
HIK.L Sortino Ratio Rank: 10
HIK.L Omega Ratio Rank: 7
HIK.L Calmar Ratio Rank: 16
HIK.L Martin Ratio Rank: 10

^GSPC

^GSPC Risk / Return Rank: 58
^GSPC Sharpe Ratio Rank: 52
^GSPC Sortino Ratio Rank: 55
^GSPC Omega Ratio Rank: 59
^GSPC Calmar Ratio Rank: 52
^GSPC Martin Ratio Rank: 71

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

HIK.L vs. ^GSPC - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Hikma Pharmaceuticals plc (HIK.L) and S&P 500 Index (^GSPC). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	HIK.L	^GSPC	Difference
Sharpe ratio Return per unit of total volatility	-0.87	0.73	-1.60
Sortino ratio Return per unit of downside risk	-1.02	1.14	-2.16
Omega ratio Gain probability vs. loss probability	0.84	1.18	-0.34
Calmar ratio Return relative to maximum drawdown	-0.69	1.19	-1.88
Martin ratio Return relative to average drawdown	-1.40	4.63	-6.03
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

HIK.L vs. ^GSPC - Sharpe Ratio Comparison

The current HIK.L Sharpe Ratio is -0.87, which is lower than the ^GSPC Sharpe Ratio of 0.73. The chart below compares the historical Sharpe Ratios of HIK.L and ^GSPC, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	HIK.L	^GSPC	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.87	0.73	-1.60
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.29	0.71	-1.01
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	-0.06	0.72	-0.79
Sharpe Ratio (All Time) Calculated using the full available price history	0.30	0.55	-0.24

Correlation

The correlation between HIK.L and ^GSPC is 0.19, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Drawdowns

HIK.L vs. ^GSPC - Drawdown Comparison

The maximum HIK.L drawdown since its inception was -67.40%, which is greater than ^GSPC's maximum drawdown of -37.67%. Use the drawdown chart below to compare losses from any high point for HIK.L and ^GSPC.

Drawdown Indicators

	HIK.L	^GSPC	Difference
Max Drawdown Largest peak-to-trough decline	-67.40%	-56.78%	-10.62%
Max Drawdown (1Y) Largest decline over 1 year	-43.71%	-9.10%	-34.61%
Max Drawdown (5Y) Largest decline over 5 years	-54.46%	-25.43%	-29.03%
Max Drawdown (10Y) Largest decline over 10 years	-67.40%	-33.92%	-33.48%
Current Drawdown Current decline from peak	-43.63%	-5.67%	-37.96%
Average Drawdown Average peak-to-trough decline	-19.39%	-10.75%	-8.64%
Ulcer Index Depth and duration of drawdowns from previous peaks	21.51%	2.62%	+18.89%

Volatility

HIK.L vs. ^GSPC - Volatility Comparison

Hikma Pharmaceuticals plc (HIK.L) has a higher volatility of 7.63% compared to S&P 500 Index (^GSPC) at 4.50%. This indicates that HIK.L's price experiences larger fluctuations and is considered to be riskier than ^GSPC based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	HIK.L	^GSPC	Difference
Volatility (1M) Calculated over the trailing 1-month period	7.63%	4.50%	+3.13%
Volatility (6M) Calculated over the trailing 6-month period	29.60%	9.50%	+20.10%
Volatility (1Y) Calculated over the trailing 1-year period	33.74%	18.75%	+14.99%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	27.65%	15.89%	+11.76%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	31.61%	18.16%	+13.45%